Free Trial

Prime Medicine's (PRME) "Buy" Rating Reaffirmed at Chardan Capital

Prime Medicine logo with Medical background
Remove Ads

Chardan Capital restated their buy rating on shares of Prime Medicine (NYSE:PRME - Free Report) in a research report report published on Monday,Benzinga reports. The brokerage currently has a $15.00 price objective on the stock.

Several other research analysts have also recently issued reports on the stock. JMP Securities began coverage on shares of Prime Medicine in a report on Tuesday, December 10th. They issued an "outperform" rating and a $10.00 target price on the stock. StockNews.com upgraded shares of Prime Medicine to a "sell" rating in a research report on Tuesday, February 11th. Guggenheim reissued a "buy" rating and issued a $18.00 target price on shares of Prime Medicine in a research note on Tuesday, December 3rd. Wedbush reaffirmed an "outperform" rating and set a $12.00 price target on shares of Prime Medicine in a research report on Friday, February 28th. Finally, Citizens Jmp upgraded Prime Medicine to a "strong-buy" rating in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $13.13.

Check Out Our Latest Analysis on PRME

Remove Ads

Prime Medicine Stock Performance

PRME traded down $0.01 during midday trading on Monday, hitting $2.30. The stock had a trading volume of 1,225,802 shares, compared to its average volume of 1,003,933. Prime Medicine has a 1 year low of $2.12 and a 1 year high of $8.58. The business has a fifty day moving average of $2.82 and a 200 day moving average of $3.38. The company has a market cap of $301.67 million, a P/E ratio of -1.12 and a beta of 1.86.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. increased its position in shares of Prime Medicine by 4.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,977,828 shares of the company's stock worth $11,616,000 after acquiring an additional 170,541 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Prime Medicine by 2.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,584,476 shares of the company's stock worth $4,628,000 after purchasing an additional 38,515 shares in the last quarter. Geode Capital Management LLC increased its holdings in Prime Medicine by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 1,467,606 shares of the company's stock worth $4,287,000 after purchasing an additional 107,627 shares during the period. State Street Corp increased its holdings in Prime Medicine by 3.9% during the 3rd quarter. State Street Corp now owns 1,146,949 shares of the company's stock worth $4,439,000 after purchasing an additional 43,086 shares during the period. Finally, Vestal Point Capital LP raised its position in Prime Medicine by 137.8% during the 3rd quarter. Vestal Point Capital LP now owns 1,070,000 shares of the company's stock valued at $4,141,000 after purchasing an additional 620,000 shares in the last quarter. 70.37% of the stock is currently owned by institutional investors.

About Prime Medicine

(Get Free Report)

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Read More

Analyst Recommendations for Prime Medicine (NYSE:PRME)

Should You Invest $1,000 in Prime Medicine Right Now?

Before you consider Prime Medicine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.

While Prime Medicine currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads